Seres Therapeutics Inc (MCRB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.27M
Last updated: Nov 17, 2026 at 11:05 AM ET
Seres Therapeutics Inc (MCRB) Competitors
The companies most similar to Seres Therapeutics are Marker Therapeutics (MRKR), Serina Therapeutics (SER) and Plus Therapeutics (PSTV). By market cap, Seres Therapeutics ranks 9th of the 13 companies on this page; Serina Therapeutics (SER) is the largest at $36.93M.
Peer Comparison
MCRB's revenue growth of 68.9% is above the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Seres Therapeutics (MCRB) | $14.27M | N/A | 6.6x | 0.0% | N/A | 68.9% | 0.00% |
| Marker Therapeutics Inc (MRKR) | $14.51M | N/A | 14.5x | -245.5% | N/A | -51.0% | 0.00% |
| Serina Therapeutics Inc (SER) | $36.93M | N/A | 288.7x | 0.0% | -109.4% | 154.9% | 0.00% |
| Plus Therapeutics Inc (PSTV) | $26.64M | N/A | 2.0x | -230.2% | -827.8% | -2.9% | 0.00% |
| Pluri Inc. (PLUR) | $15.09M | N/A | 8.7x | 0.0% | -650.8% | -15.8% | 0.00% |
| Cyclerion Therapeutics Inc (CYCN) | $15.73M | N/A | N/A | 0.0% | N/A | -43.2% | 0.00% |
| Tvardi Therapeutics, Inc. (TVRD) | $15.74M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tempest Therapeutics Inc (TPST) | $7.64M | N/A | N/A | 0.0% | -783.6% | 0.0% | 0.00% |
| Theriva Biologics Inc. (TOVX) | $6.61M | N/A | 21.5x | 0.0% | -52.3% | 0.0% | 0.00% |
| Context Therapeutics Inc (CNTX) | $16.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Biovie Inc (BIVI) | $12.12M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tscan Therapeutics Inc (TCRX) | $10.89M | N/A | 3.6x | 0.0% | -129.7% | -65.8% | 0.00% |
| Transcode Therapeutics Inc (RNAZ) | $22.35M | N/A | N/A | 0.0% | -412.7% | 0.0% | 0.00% |
| Peer median | $15.41M | N/A | 11.6x | 0.0% | -412.7% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Seres Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Marker Therapeutics Inc (MRKR) | Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based... | MRKR competitors |
| Serina Therapeutics Inc (SER) | Serina Therapeutics Inc is a pioneering biotechnology company focused on developing innovative solutions for unmet medical needs in oncology and neurology... | SER competitors |
| Plus Therapeutics Inc (PSTV) | Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing... | PSTV competitors |
| Pluri Inc. (PLUR) | Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy... | PLUR competitors |
| Cyclerion Therapeutics Inc (CYCN) | Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development... | |
| Tvardi Therapeutics, Inc. (TVRD) | Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet... | TVRD competitors |
| Tempest Therapeutics Inc (TPST) | Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated... | TPST competitors |
| Theriva Biologics Inc. (TOVX) | Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. | TOVX competitors |
| Context Therapeutics Inc (CNTX) | Centrexion Therapeutics Corporation, a late-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel, non-opioid... | CNTX competitors |
| Biovie Inc (BIVI) | BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States. | BIVI competitors |
| Tscan Therapeutics Inc (TCRX) | Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor... | TCRX competitors |
| Transcode Therapeutics Inc (RNAZ) | TransCode Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of drugs for the treatment of metastatic... | RNAZ competitors |
Frequently Asked Questions About MCRB
Who are Seres Therapeutics' main competitors?
The companies most similar to Seres Therapeutics include Marker Therapeutics (MRKR), Serina Therapeutics (SER), Plus Therapeutics (PSTV), Pluri (PLUR) and Cyclerion Therapeutics (CYCN), listed from the closest match.
Who is Seres Therapeutics' biggest competitor?
Serina Therapeutics (SER) is the largest of the similar companies at $36.93M; Marker Therapeutics (MRKR) is the closest match by business profile, size, sector and industry.
How does MCRB stock compare with its competitors?
MCRB's P/S is 6.6x against a peer median of 11.6x; its net margin is 0.0% against a peer median of 0.0%.
Which of Seres Therapeutics' competitors pays a higher dividend?
Seres Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Seres Therapeutics bigger than its competitors?
No. Seres Therapeutics is 9th by market cap among the 13 companies on this page; the largest is Serina Therapeutics (SER) at $36.93M.
MCRB pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors